Advertisement

Dopamine Receptors and Clinical Medicine

  • Ross J. Baldessarini
Part of the The Receptors book series (REC)

Abstract

Other chapters in this volume document the explosive recent advances in the genetic, neuroanatomical, and molecular pharmacological understanding of both the traditional and most prevalent D1* and D2L dopamine (DA) receptors and their recently discovered subtypes, D2S, D3, D4, and D5 (1–4). These advances promise to yield important contributions to clinical medicine. The localization of the genes for each of the identified DA receptors to specific regions of human chromosomes has stimulated many studies seeking evidence of genetic linkage in specific clinical conditions, particularly psychiatric and neurological disorders. There is also much progress in the development of DA receptor type-selective radioligands for application in postmortem neuropathological analyses and for positron emission tomography (PET) or single photon emission computed tomography (SPECT) of the brain for clinical applications. Finally, the discovery of the novel DA receptor types, and of apparently selective localization of types D3 and D4 to limbic or other nonextrapyramidal regions of forebrain, has stimulated a vigorous search for small-molecule ligands selective for these targets as potential psychotropic medicinal agents.

Keywords

Positron Emission Tomography Single Photon Emission Compute Tomography Dopamine Receptor Tardive Dyskinesia Positron Emission Tomography Study 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Civelli, O., Bunzow, J. R., and Grandy, D. K. (1993) Molecular diversity of the dopamine receptors. Annu. Rev. Pharmacol. Toxicol. 32, 281–307.CrossRefGoogle Scholar
  2. 2.
    De Keyser, J. (1993) Subtypes and localization of dopamine receptors in human brain. Neurochem. Int. 22, 83–93.PubMedCrossRefGoogle Scholar
  3. 3.
    Gingrich, J. A. and Caron, M. G. (1993) Recent advances in the molecular biology of dopamine receptors. Ann. Rev. Neurosci. 16, 299–321.PubMedCrossRefGoogle Scholar
  4. 4.
    Hall, H., Sedvall, G., Manusson, O., Kopp, J., Halldin, C., and Farde, L. O. (1994) Distribution ofD1 and D2 dopamine receptors, and dopamine and its metabolites in the human brain. Neuropsychopharmacology 11, 245–256.PubMedCrossRefGoogle Scholar
  5. 5.
    Baldessarini, R. J. (1996) Drugs and the treatment of psychiatric disorders, in Goodman and Gilman ‘s The Pharmacologic Basis of Therapeutics, 9th ed. ( Harden, W., Rudin, W., Molinoff, P. B., and Rall, T., eds.), McGraw-Hill, New York, pp. 399–459.Google Scholar
  6. 6.
    Baldessarini, R. J. (1996) Chemotherapy in Psychiatry: Principles and Practice,3rd ed. Harvard University Press, Cambridge, MA, in press.Google Scholar
  7. 7.
    Davis, K. L., Kann, R. S., Ko, G., and Davidson, M. (1991) Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry 148, 1474–1486.PubMedGoogle Scholar
  8. 8.
    Lieberman, J. A. and Koreen, A. R. (1993) Neurochemistry and neuroendocrinology of schizophrenia: a selective review. Schizophrenia Bull. 19, 371–429.CrossRefGoogle Scholar
  9. 9.
    Meltzer, H. Y. and Stahl, S. M. (1976) The dopamine hypothesis of schizophrenia: a review. Schizophrenia Bull. 2, 19–76.CrossRefGoogle Scholar
  10. 10.
    Reynolds, G. P. (1989) Beyond the dopamine hypothesis: the neurochemical pathology of schizophrenia. Br. J. Psychiatry 155, 305–316.PubMedGoogle Scholar
  11. 11.
    Seeman, P. (1987) Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1, 133–152.PubMedCrossRefGoogle Scholar
  12. 12.
    Gessa, G. L. and Serra, G (eds.) (1990) Dopamine and Mental Depression. Pergamon, Oxford, UK.Google Scholar
  13. 13.
    Sunahara, R. K., Niznik, H. B., Weiner, D. M., Stormann, T. M., Brann, M. R., Kennedy, J. L., Gelernter, J. E., Rozmahel, R., Yang, Y., Israel, Y., Seeman, P., and O’Dowd, B. F. (1990) Human dopamine D, receptor encoded by an intronless gene on chromosome 5. Nature 347, 80–83.PubMedCrossRefGoogle Scholar
  14. 14.
    Sherrington, R., Mankoo, B., Attwood, J., Kalsi, G., Curtis, D., Buetow, K., Povey, S., and Gurling, H. (1993) Cloning of the human dopamine D5 receptor gene and identification of a highly polymorphic microsatellite for the DRD5 locus that shows tight linkage to the chromosome 4p reference marker RAF-1P1. Genomics 18, 423–425.PubMedCrossRefGoogle Scholar
  15. 15.
    Grandy, D. K., Litt, M., Allen, L., Bunzow, J. R., Marchionni, M., Makam, H., Reed, L., Megenis, R. E., and Civelli, O. (1989) The human dopamine D2 receptor gene is located on chromosome 11 at q22-q23 and identifies a Taq-1 RFLP. Am. J. Hum. Genetics 45, 778–785.Google Scholar
  16. 16.
    Huage, X. Y., Grandy, D. R., Eubanks, J. H., Evans, G. A., Civelli, O., and Litt, M. (1991) Detection and characterization of additional DNA polymorphisms in the dopamine D2 receptor gene. Genomics 10, 527–530.CrossRefGoogle Scholar
  17. 17.
    Lannfelt, L., Sokoloff, P., Martres, M.-P., Pilon, C., Giros, B., Jönsson, E., Sedvall, G., and Schwartz, J.-C. (1992) Amino acid substitution in the dopamine D3 receptor as a useful polymorphism for investigating psychiatric disorders. Psychiatr. Genetics 2, 249–256.CrossRefGoogle Scholar
  18. 18.
    Kennedy, J. L., Sidenberg, D. G., Van Tol, H. H., and Kidd, K. K. (1991) A Hinc-II RFLP in the human D4 dopamine receptor locus (DRD4). Nucleic Acids Res. 19, 5801, 5802.Google Scholar
  19. 19.
    Gelernter, J., Kennedy, J. L., Van Tol, H. H., Civelli, O., and Kidd, K. K. (1992) The D4 dopamine receptor (DRD4) maps to distal l 1p close to HRAS. Genomics 13, 208–210.PubMedCrossRefGoogle Scholar
  20. 20.
    Van Tol, H. H., Bunzow, J. R., Guan, H.-C., Sunahara, R. K., Seeman, P., Niznik, H. B., and Civelli, O. (1991). Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350, 610–614.PubMedCrossRefGoogle Scholar
  21. 21.
    Brett, P. M., Curtis, D., Robertson, M. M., and Gurling, H. M. (1995) The genetic susceptibility to Gilles de la Tourette syndrome in a large multiplex affected British kindred: linkage analysis excludes a role for the genes coding for dopamine Di, D2, D3, D4, D5 receptors, dopamine beta-hydroxylase, tyrosinase, and tyrosine hydroxylase. Biol. Psychiatry 37, 533–540.PubMedCrossRefGoogle Scholar
  22. 22.
    Kendler, K. S. and Diehl, S. R. (1993) The genetics of schizophrenia: a current genetic-epidemiologic perspective. Schizophrenia Bull. 19, 261–285.CrossRefGoogle Scholar
  23. 23.
    Kety, S. S., Wender, P. H., Jacobsen, B., Ingraham, L. J., Jansson, L., Faber, B., and Kinney, D. K. (1994) Mental illness in the biological and adoptive relatives of schizophrenic adoptees. Arch. Gen. Psychiatry 51, 442–455.PubMedCrossRefGoogle Scholar
  24. 24.
    Carpenter, W. T. and Buchanan, R. W. (1994) Schizophrenia. N. Engl. J. Med. 330, 681–690.PubMedCrossRefGoogle Scholar
  25. 25.
    Crow, T. J. (1980) Molecular pathology of schizophrenia: more than one disease process. Br. Med. J. 280, 60–68.CrossRefGoogle Scholar
  26. 26.
    Crow, T. J. (1986) The continuum of psychosis and its implications for the structure of the gene. Br. J. Psychiatry 149, 419–429.PubMedCrossRefGoogle Scholar
  27. 27.
    Crowe, R. R. (1993) Candidate genes in psychiatry: an epidemiological perspective. Am J. Med. Genetics (Neuropsychiatric) 48, 74–77.CrossRefGoogle Scholar
  28. 28.
    Taylor, M. A., Berenbaum, S. A., Jampala, V. C., and Cloninger, C. R. (1993) Are schizophrenia and affective disorder related? Preliminary data from a family study. Am. J. Psychiatry 150, 278–285.PubMedGoogle Scholar
  29. 29.
    Wright, I. and Woodruff, P. (1995) Aetiology of schizophrenia: a review of theories and their clinical and therapeutic implications. CNS Drugs 3, 126–144.CrossRefGoogle Scholar
  30. 30.
    Loranger, A. W. (1981) Genetic independence of manic-depression and schizophrenia. Acta Psychiatr. Scand. 63, 444–452.PubMedCrossRefGoogle Scholar
  31. 31.
    Kraepelin, E. (1919) Dementia Prcecox and Paraphrenia (Barclay, R. M. and Robertson, G. M., trans.), Livingstone, Edinburgh, UK.Google Scholar
  32. 32.
    Kraepelin, E. (1921)Manic-Depressive Insanity and Paranoia(Barclay, R. M. and Robertson, G. M., trans.), Livingstone, Edinburgh, UK.Google Scholar
  33. 33.
    Byerley, W., Plaetke, R., Jensen, S., Holik, J., Hoff, M., Myles-Worsley, M., Wender, P., Reimherr, F., Leppert, M., O’Connell, P., Lalouel, J., and White, R. (1991) Linkage analysis of six schizophrenia pedigrees with 150 DNA markers. Schizophrenia Res. 4, 274, 275.Google Scholar
  34. 34.
    Wildenauer, D. B., Schwab, S., Würl, D., Ertl, M., Ackenheil, M., Schmidt, S., Drews, B., Schmidt, F., Hallmayer, J., and Maier, W. (1991) Linkage analysis in schizophrenia: exclusion of 5g11—q13, 5q34-qtr, 11g22, 23, Xpter and chromosome 19 in 15 systematically ascertained European families. Am. J. Hum. Genetics 49 (Suppl. 4), 363.Google Scholar
  35. 35.
    Jensen, S., Plaetke, R., Holik, J., Hoff, M., Myles-Worsley, M., Leppert, M., Coon, H., Vest, K., Freedman, R., Waldo, M., Zhou, Q.-Y., Litt, M., Civelli, O., and Byerley, W. (1993) Linkage analysis of schizophrenia: the DI dopamine receptor gene and several flanking DNA markers. Hum. Heredity 43, 58–62.PubMedCrossRefGoogle Scholar
  36. 36.
    Campion, D., d’Amato, T., Bastard, C., Laurent, C., Guedj, F., Jay, M., Dollfus, S., Thibault, F., Petit, M., Gorwood, P., Babron, M. C., Waksman, G., Martinez, M., and Mallet, J. (1994) Genetic study of dopamine D1, D2, and D4 receptors in schizophrenia. Psychiatry Res. 51, 215–230.PubMedCrossRefGoogle Scholar
  37. 37.
    Cichon, S., Nöthen, M. M., Rietschel, M., Körner, J., and Propping, P. (1994) Single-strand conformation analysis (SSCA) of the dopamine Di receptor gene (DRD 1) reveals no significant mutation in patients with schizophrenia and manic-depression. Biol. Psychiatry 36, 850–853.PubMedCrossRefGoogle Scholar
  38. 38.
    Dollfus, S., Campion, D., Vasse, T., Preterre, P., Laurent, C., d’Amato, T., Thibault, F., Mallet, J., and Petit, M. (1995) Association between dopamine DI, D2, D3, and D4 receptor genes and schizophrenia defined by 13 diagnostic systems. Schizophrenia Res. 15(1–2), 37, 38.Google Scholar
  39. 39.
    Coon, H., Byerley, W., Holik, J., Hoff, M., Myles-Worsley, M., Lannfelt, L., Sokoloff, P., Schwartz, J.-C., Waldo, M., Freedman, R., and Plaetke, R. (1993) Linkage analysis of schizophrenia with five dopamine receptor genes in nine pedigrees. Am. J. Hum. Genetics 52, 327–334.Google Scholar
  40. 40.
    Ravindranathan, A., Coon, H., DeLisi, L., Holik, J., Hoff, M., Brown, A., Shields, G., Crow, T., and Byerley, W. (1994) Linkage analysis between schizophrenia and a microsatellite polymorphism for the D5 dopamine receptor gene. Psychiatr. Genetics 4, 77–80.CrossRefGoogle Scholar
  41. 41.
    Moises, H. W., Gelernter, J., Guiffa, L. A., Zarcone, V., Wetterberg, L., Civelli, O., Kidd, K. K., Cavalli-Szforza, L. L., Grandy, D. K., Kennedy, J. L., Vinogradov, S., Mauer, J., Litt, M., and Sjögren, B. (1991) No linkage between D2 dopamine receptor gene region and schizophrenia. Arch. Gen. Psychiatry 48, 643–647.PubMedCrossRefGoogle Scholar
  42. 42.
    Sarkar, G., Kapelner, S., Grandy, D. K., Marchionni, M., Civelli, O., Sobell, J., Heston, L., and Sommer, S. S. (1991) Direct sequencing of the dopamine D2 receptor (DRD2) in schizophrenics reveals three polymorphisms but no structural changes in the receptor. Genomics 11, 8–14.PubMedCrossRefGoogle Scholar
  43. 43.
    Gill, M., McGuffin, P., Parfitt, E., Mant, R., Asherson, D., Collier, D., Vallada, H., Powell, J., Shaikh, S., Taylor, C., Sargeant, M., Clements, A., Nanko, S., Takazawa, N., Llewellyn, D., Williams, J., Whatley, S., Murray, R., and Owen, M. (1993) A linkage study of schizophrenia with DNA markers from the long arm of chromosome 11. Psychol. Med. 23, 27–44.PubMedCrossRefGoogle Scholar
  44. 44.
    Su, Y., Burke, J., O’Neill, F. A., Murphy, B., Nie, L., Kipps, B., Bray, J., Skinkwin, R., Nuallain, M. N., MacLean, C., Walsh, D., Diehl, S. R., and Kendler, J. S. (1993) Exclusion of linkage between schizophrenia and the D2 dopamine receptor gene region of chromosome l l q in 112 Irish multiplex families. Arch. Gen. Psychiatry 50, 205–211.PubMedCrossRefGoogle Scholar
  45. 45.
    Wang, Z., Black, D., Andreasen, N. C., and Crowe, R. R. (1993) A linkage study of chromosome l l q in schizophrenia. Arch. Gen. Psychiatry 50, 212–216.PubMedCrossRefGoogle Scholar
  46. 46.
    Gejman, P. V., Ram, A., Gelernter, J., Friedman, E., Cao, Q., Pickar, D., Blum, K., Noble, E. P., Kranzler, H. R., O’Malley, S., Hamer, D. H., Whitsitt, F., Rao, P., DeLisi, L. E., Virkkunen, M., Linnoila, M., Goldman, D., and Gershon, E. S. (1994) No structural mutation in the dopamine D2 receptor gene in alcoholism or schizophrenia. JAMA 271, 204–208.PubMedCrossRefGoogle Scholar
  47. 47.
    Hattori, M., Nanko, S., Dai, X. Y., Fukuda, R., and Kazamatsuri, H. (1994) Mismatch PCR RFLP detection of DRD2 Ser311 Cys polymorphism and schizophrenia. Biochem. Biophys. Res. Commun. 202, 757–763.PubMedCrossRefGoogle Scholar
  48. 48.
    Shaikh, S., Collier, D. A., Arranz, M., Crocq, M.-A., Gill, M., and Kerwin, R. (1995) Examination of the DRD2 (Ser-Cys) variant in schizophrenia. Schizophrenia Res. 15 (1–2), 48.Google Scholar
  49. 49.
    Nanko, S., Hattori, M., Ikeda, K., Sasaki, T., Kazamatzuri, H., and Kuwata, S. (1993) Dopamine D4 receptor polymorphism and schizophrenia. Lancet 341, 689, 690.Google Scholar
  50. 50.
    Wiese, C., Lannfelt, L., Kristbjarnarson, H., Yang, L., Zoega, T., Sokoloff, P., Ivarsson, O., Schwartz, J.-C., Moises, H. W., and Helgason, T. (1993) No evidence of linkage between schizophrenia and D3 receptor gene locus in Icelandic pedigrees. Psychiatry Res. 46, 69–78.PubMedCrossRefGoogle Scholar
  51. 51.
    Sabaté, O., Campion, D., d’Amato, T., Martres, M. P., Sokoloff, P., Giros, B., Leboyer, M., Jay, M., Guedj, F., Thbault, F., Dollfus, S., Preterre, P., Petit, M., Bobron, M.-C., Waksman, G., Mallet, J., and Schwartz, J.-C. (1994) Failure to find evidence for linkage or association between the dopamine D3 receptor gene and schizophrenia. Am. J. Psychiatry 151, 107–111.PubMedGoogle Scholar
  52. 52.
    Crocq, M. A., Duval, F., Mayerova, A., Sokoloff, P., Mokrani, M. C., and Macher, J. P. (1995) Clinical and functional correlates of a dopamine D3 receptor polymorphism. Hum. Psychopharmacol. 10, 19–24.CrossRefGoogle Scholar
  53. 53.
    Barr, C. L., Kennedy, J. L., Lichter, J. B., Van Tol, H. H., Wetterberg, L., Livak, K. J., and Kidd, K. K. (1993) Alleles at the dopamine D4 receptor locus do not contribute to the genetic susceptibility to schizophrenia in a large Swedish kindred. Am. J. Med. Genetics (Neuropsychiatric) 48, 218–222.CrossRefGoogle Scholar
  54. 54.
    Debryn, A., Mandelbaum, K., Sandkuijl, L. A., Delvenne, V., Hirsch, D., Staner, L., Mendlewicz, J., and Van Broeckhoven, C. (1994) Nonlinkage of bipolar illness to tyrosine hydroxylase, tyrosinase, and D2 and D4 dopamine receptor genes on chromosome 11. Am. J. Psychiatry 151, 1202–1206.Google Scholar
  55. 55.
    Macciardi, F., Petronis, A., Van Tol, H. H., Marino, C., Cavallini, C., Smeraldi, E., and Kennedy, J. L. (1994) Analysis of the D4 dopamine receptor gene variant in an Italian schizophrenia kindred. Arch. Gen. Psychiatry 51, 288–293.PubMedCrossRefGoogle Scholar
  56. 56.
    Rao, P. A., Pickar, D., Gejman, P. V., Ram, A., Gershon, E. S., and Gelernter, J. (1994) Allelic variation in the D4 dopamine receptor (DRD4) gene does not predict response to clozapine. Arch. Gen. Psychiatry 51, 912–917.PubMedCrossRefGoogle Scholar
  57. 57.
    Catalano, M., Nobile, M., Novelli, E., Nöthen, M. M., and Smeraldi, E. (1993) Distribution of a novel mutation in the first exon of the human dopamine D4 receptor gene in psychotic patients. Biol. Psychiatry 34, 459–464.PubMedCrossRefGoogle Scholar
  58. 58.
    Holmes, D., Brynjolfsson, J., Brett, P., Curtis, D., Pertursson, H., Sherrington, R., and Gurling, H. (1991) No evidence of a susceptibility locus predisposing to manic-depression in the region of the dopamine (D2) receptor gene. Br. J. Psychiatry 158, 635–641.PubMedCrossRefGoogle Scholar
  59. 59.
    Blum, K., Noble, E. P., Sheridan, P. J., Montgomery, A., Ritchie, T., Jagadeeswaran, P., Nogami, H., Briggs, A. H., and Cohn, J. B. (1990) Allelic association of human dopamine D, receptor gene in alcoholism. JAMA 263, 2055–2060.PubMedCrossRefGoogle Scholar
  60. 60.
    Noble, E. P., Blum, K., Ritchie, T., Montgomery, A., and Sheridan, P. J. (1991) Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. Arch. Gen. Psychiatry 48, 648–654.PubMedCrossRefGoogle Scholar
  61. 61.
    Bolos, A. M., Dean, M., Lucas-Derse, S., Ramsburg, M., Brown, G. L., and Goldman, D. (1990) Population and pedigree studies reveal a lack of association between the dopamine D2 receptor gene and alcoholism. JAMA 264, 3156–3160.PubMedCrossRefGoogle Scholar
  62. 62.
    Gelernter, J., O’Malley, S., Risch, N., Kranzler, H. R., Krystal, J., Merikangas, K., Kennedy, J. L., and Kidd, K. K. (1991) No association between an allele at the D2 dopamine receptor gene (DRD2) and alcoholism. JAMA 266, 1801–1807.PubMedCrossRefGoogle Scholar
  63. 63.
    Parsian, A., Todd, R. D., Devor, E. J., O’Malley, K. L., Suarez, B. K., Reich, T., and Cloninger, C. R. (1991) Alcoholism and alleles of the human D2 dopamine receptor locus. Arch. Gen. Psychiatry 48, 655–663.PubMedCrossRefGoogle Scholar
  64. 64.
    Noble, E. P. (1993) The D2 dopamine receptor gene: a review of association studies in alcoholism. Behay. Genetics. 23, 119–129.CrossRefGoogle Scholar
  65. 65.
    Comings, D. E. (1994) The dopamine D2 receptor gene (DRD2) and neuropsychiatric disorders. CNS Drugs 1, 1–5.Google Scholar
  66. 66.
    Conneally, P. M. (1991) Association between the D2 dopamine receptor gene and alcoholism. Arch. Gen. Psychiatry 48, 664–666.CrossRefGoogle Scholar
  67. 67.
    Devor, E. J. (1984) Complex segregation analysis of Gilles de la Tourette syndrome: further evidence for a major locus mode of transmission. Am. J. Hum. Genetics 36, 704–709.Google Scholar
  68. 68.
    Gelernter, J., Pakstis, A., Pauls, D. L., Kurlan, R., Grancher, S. T., Civelli, O., Grandy, D., and Kidd, K. K. (1990) Tourette syndrome is not linked to D2 dopamine receptor. Arch. Gen. Psychiatry 47, 1073–1077.PubMedCrossRefGoogle Scholar
  69. 69.
    Gelernter, J., Kennedy, J. L., Grandy, D. K., Zhou, Q.-Y., Civelli, O., Pauls, D. L., Pakstis, A., Kurlan, R., Sunahara, R. K., Niznik, H. B., O’Dowd, B., Seeman, P., and Kidd, K. K. (1993) Exclusion of close linkage of Tourette’s syndrome to DI dopamine receptor. Am. J. Psychiatry 150, 449–453.PubMedGoogle Scholar
  70. 70.
    Landwehrmeyer, B., Mengod, G., and Palacios, J. M. (1993) Differential visualization of dopamine DZ and D3 receptor sites in rat brain: a comparative study using in situ hybridization histochemistry and ligand binding autoradiography. Eur. J. Neurosci. 5, 145–153.PubMedCrossRefGoogle Scholar
  71. 71.
    Lévesque, D., Diaz, J., Pilon, C., Martres, M.-P., Giros, B., Souil, E., Schott, D., Morgat, J.-L., Schwartz, J.-C., and Sokoloff, P. (1992) Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7[3H]hydroxyN,N-di-n-propyl-2-aminotetralin. Proc. Natl. Acad. Sci. USA 89, 8155–8159.PubMedCrossRefGoogle Scholar
  72. 72.
    Crocq, M. A., Mant, R., Asherson, P., Williams, J., Hode, Y., Mayerova, A., Collier, D., Lannfelt, L., Sokoloff, P., Gill, M., Macher, J. P., McGuffin, P., and Owen, M. J. (1992) Association between schizophrenia and homozygosity at the dopamine D3 receptor gene. J. Med. Genetics 29, 858–860.CrossRefGoogle Scholar
  73. 73.
    Mant, R., Williams, J., Asherson, P., Parfitt, E., McGuffin, P., and Owen, M. J. (1994) Relationship between homozygosity at the dopamine D3 receptor gene and schizophrenia. Am. J. Med. Genetics (Neuropsychiatric) 54, 21–26.CrossRefGoogle Scholar
  74. 74.
    Jönsson, E., Lannfelt, L., Sokoloff, P., Schwartz, J.-C., and Sedvall, G. (1993) Lack of association in a Bal-I polymorphism in the dopamine D3 receptor gene in schizophrenia. Acta Psychiatr. Scand. 87, 345–347.PubMedCrossRefGoogle Scholar
  75. 75.
    Laurent, C., Savoye, C., Samolyk, D., Meloni, R., Mallet, J., Campion, D., Martinez, M., d’ Amato, T., Bastard, C., and Dollfus, S. (1994) Homozygosity at the dopamine D3 receptor locus is not associated with schizophrenia. J. Med. Genetics 31, 260–264.CrossRefGoogle Scholar
  76. 76.
    Nanko, S., Sasaki, T., Fukuda, R., Hattori, M., Dai, X. Y., Kazamatzuri, H., Kuwata, S., Juri, T., and Gill, M. (1993) A study of the association between schizophrenia and the dopamine D3 receptor gene. Hum. Genetics 92, 336–338.CrossRefGoogle Scholar
  77. 77.
    Nimgaonkar, V. L., Zhang, X. R., Caldwell, J. G., Ganguli, R., and Chakravarti, A. (1993) Association study of schizophrenia with dopamine D3 receptor gene polymorphisms: probable effects of family history of schizophrenia? Am. J. Med. Genetics (Neuropsychiatric) 48, 214–217.CrossRefGoogle Scholar
  78. 78.
    Nöthen, M. M., Cichon, S., Propping, P., Fimmers, R., Schwab, S. G., and Wildenauer, D. P. (1993) Excess of homozygosity at the dopamine D3 receptor gene not confirmed. J. Med. Genetics 30, 708–712.CrossRefGoogle Scholar
  79. 79.
    Yang, L., Li, T., Wiese, C., Lannfelt, L., Sokoloff, P., Xu, C. T., Zeng, Z., Schwartz, J. C., and Moises, H. W. (1993) No association between schizophrenia and homozygosity at the D3 dopamine receptor gene. Am. J. Med. Genetics (Neuropsychiatric) 48, 83–86.CrossRefGoogle Scholar
  80. 80.
    Nimgaonkar, V. L., Zhang, X. R., Brar, J., DeLeo, M., Hogge, W., Ganguli, R., and Chakravarti, A. (1995) Association between the dopamine D3 receptor gene locus and liability to schizophrenia, as well as its age of onset. Schizophrenia Res. 15 (1–2), 45.CrossRefGoogle Scholar
  81. 81.
    Van Tol, H. H., Wu, C. M., Guan, H.-C., Ohara, K., Bunzow, J. R., Civelli, O., Kennedy, J., Seeman, P., Niznik, H. B., and Janovic, V. (1992) Multiple dopamine D4 receptor variants in the human population. Nature 358, 149–152.PubMedCrossRefGoogle Scholar
  82. 82.
    Shaikh, S., Collier, D. A., Kerwin, R. W., Pilowsky, L. S., Gill, M., Xu, W.-M., and Thornton, A. (1993) Dopamine D4 receptor subtypes and response to clozapine. Lancet 341, 116.PubMedCrossRefGoogle Scholar
  83. 83.
    Shaikh, S., Gill, M., Owen, M., Asherson, P., McGuffin, P., Nanko, S., Murray, R. M., and Collier, D. A. (1994) Failure to find linkage between a functional polymorphism in the dopamine D4 receptor gene and schizophrenia. Am. J. Med. Genetics 54, 8–I1.CrossRefGoogle Scholar
  84. 84.
    Baldessarini, R. J., Gardner, D. M., and Garver, D. L. (1995) Conversions from clozapine to other antipsychotics. Arch. Gen. Psychiatry 52, 1071, 1072.Google Scholar
  85. 85.
    Seeman, P. (1992) Dopamine receptor sequences: therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology 7, 261–284.PubMedGoogle Scholar
  86. 86.
    Baldessarini, R. J. and Frankenburg, F. R. (1991) Clozapine—a novel antipsychotic agent. N. Engl. J. Med. 324, 746–754.PubMedCrossRefGoogle Scholar
  87. 87.
    Lahti, R. A., Roberts, R. C., and Tamminga, C. A. (1995) D2-Family receptor distributions in human postmortem tissue: an autoradiographic study. NeuroReport 6, 2505–2512.PubMedCrossRefGoogle Scholar
  88. 88.
    Murray, A. M., Hyde, T. M., Knable, M. B., Herman, M. M., Bigelow, L. B., Carter, J. M., Weinberger, D. R., and Kleinman, J. E. (1995) Distribution of putative D4 dopamine receptors in postmortem striatum from patients with schizophrenia. J. Neurosci. 15, 2186–2191.PubMedGoogle Scholar
  89. 89.
    O’Malley, K. L., Harmon, S., Tang, L., and Todd, R. D. (1992) The rat dopamine D4 receptor: sequence, gene structure, and demonstration of expression in the cardiovascular system New Biologist 4, 137–146.PubMedGoogle Scholar
  90. 90.
    Reynolds, G. P. and Mason, S. L. (1994) Are striatal dopamine D4 receptors increased in schizophrenia? J. Neurochem. 63, 1576–1577.PubMedCrossRefGoogle Scholar
  91. 91.
    Seeman, P., Guan, H.-C., and Van Tol, H. H. (1993) Dopamine D4 receptors elevated in schizophrenia. Nature 365, 441–445.PubMedCrossRefGoogle Scholar
  92. 92.
    Amara, S. G. and Kuhar, M. J. (1993) Neurotransmitter transporters: recent progress. Annu. Rev. Neurosci. 16, 73–93.PubMedCrossRefGoogle Scholar
  93. 93.
    Schloss, P., Wayser, W., and Betz, H. (1992) Neurotransmitter transporters: a novel family of integral plasma membrane proteins. FEBS Lett. 307, 76–80.PubMedCrossRefGoogle Scholar
  94. 94.
    Persico, A. M., Wang, Z. W., Black, D. W., Andreasen, N. C., Uhl, G. R., and Crowe, R. R. (1995) The dopamine transporter gene and schizophrenia spectrum disorders: exclusion of close linkage. Am. J. Psychiatry 152, 134–136.PubMedGoogle Scholar
  95. 95.
    Joyce, J. N., Lexow, N., Bird, E. D., and Winokur, A. (1988) Organization of dopamine Di and D, receptors in human brain: receptor autoradiographic studies in Huntington’s disease and schizophrenia. Synapse 2, 546–557.PubMedCrossRefGoogle Scholar
  96. 96.
    Owen, F., Crow, T. J., Poulter, M., Cross, A. J., Longden, A., and Riley, G. J. (1978) Increased dopamine receptor sensitivity in schizophrenia. Lancet 2, 223–225.PubMedCrossRefGoogle Scholar
  97. 97.
    Lee, T. and Seeman, P. (1980) Elevation of brain neuroleptic/dopamine receptors in schizophrenia. Am. J. Psychiatry 137, 191–197.PubMedGoogle Scholar
  98. 98.
    Lee, T., Seeman, P., Tourtelotte, W. W., Farley, U. J., and Hornykiewicz, O. (1978) Binding of 3H-neuroleptics and 3H-apomorphine in schizophrenic brains. Nature 274, 897–900.PubMedCrossRefGoogle Scholar
  99. 99.
    Mackay, A. V., Bird, E. D., Spokes, E. G., Rossor, M., Iversen, L. L., Creese, I., and Snyder, S. H. (1980) Dopamine receptors and schizophrenia: drug effect or illness? Lancet 2, 915, 916.Google Scholar
  100. 100.
    Mackay, A. V., Iversen, L. L., Rossor, M., Spokes, E., Bird, E. D., Arregui, A., Creese, I., and Snyder, S. H. (1982) Increased brain dopamine and dopamine receptors in schizophrenia. Arch. Gen. Psychiatry 39, 991–997.PubMedCrossRefGoogle Scholar
  101. 101.
    Reisine, T. D., Rossor, M., and Spokes, E. G. (1980) Opiate and neuroleptic receptor alterations in human schizophrenic brain tissue, in Receptors for Neurotransmitters and Peptide Hormones ( Pepeu, G., Kuhar, M. J., and Enna, S. J., eds.), Raven, New York, pp. 443–450.Google Scholar
  102. 102.
    Cross, A. J., Crow, T. J., and Owen, F. (1981) 3H-Flupenthixol binding to postmortem brains of schizophrenics: evidence for a selective increase in dopamine D2 receptors. Psychopharmacology 74, 122–124.Google Scholar
  103. 103.
    Toru, M., Nishikawa, T., Semba, J., Mataga, N., Takashima, M., Noda, K., and Shibuya, H. (1982) Increased dopamine metabolism in the putamen and caudate in schizophrenic patients, in Psychobiology of Schizophrenia ( Namba, M. and Kaiya, H., eds.), Pergamon, Oxford, UK, pp. 235–240.Google Scholar
  104. 104.
    Cross, A. J., Crow, T. J., Ferrier, I. N., Johnstone, E. C., McCreadie, R. M., Owen, F., Owens, D. G., and Pouter, M. (1983) Dopamine receptor changes in schizophrenia in relation to the disease process and movement disorder. J. Neural Transm. 18 (Suppl.), 265–272.Google Scholar
  105. 105.
    Owen, F., Cross, A. J., and Crow, T. J. (1983) Ligand-binding studies in brains of schizophrenics, in Cell Surface Receptors ( Strange, P. G., ed.), Wiley, New York, pp. 163–183.Google Scholar
  106. 106.
    Pimoule, C., Schoemaker, H., Reynolds, G. P., and Langer, S. Z. (1985) [3H]SCH23390 labeled D, dopamine receptors are unchanged in schizophrenia and Parkinson’s disease. Eur. J. Pharmacol. 114, 235–237.Google Scholar
  107. 107.
    Mita, T., Hanada, S., Nishino, N., Kuno, T., Nakai, H., Yamadori, T., Mizoi, Y., and Tanaka, C. (1986) Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenia. Biol. Psychiatry 21, 1407–1414.PubMedCrossRefGoogle Scholar
  108. 108.
    Hess, E. J., Bracha, H. S., Kleinman, J. E., and Creese, I. (1987) Dopamine receptor subtype imbalance in schizophrenia. Life Sci. 40, 1487–1497.PubMedCrossRefGoogle Scholar
  109. 109.
    Seeman, P., Bzowej, N. H., Guan, H. C., Bergeron, C., Reynolds, G. P., Bird, E. P., Riederer, P., Jellinger, K., and Tourtellote, W. W. (1987) Human brain D, and D2 dopamine receptors in schizophrenia, Alzheimer’s, Parkinson’s, and Huntington’s diseases. Neuropsychopharmacology 1, 5–15.PubMedCrossRefGoogle Scholar
  110. 110.
    Reynolds, G. P. and Gzudek, C. (1988) Status of the dopaminergic system in postmortem brain in schizophrenia. Psychopharmacol. Bull. 24, 345–347.PubMedGoogle Scholar
  111. 111.
    Kornhuber, J., Riederer, P., Reynolds, G. P., Beckmann, H., Jellinger, K., and Gabriel, E. (1989) 3H-Spiperone binding sites in postmortem brains from schizophrenic patients: relationship to drug treatment, abnormal movements, and positive symptoms. J. Neural Transm. 75, 1–10.Google Scholar
  112. 112.
    Seeman, P., Niznik, H. B., Guan, H.-C., Booth, G., and Ulpian, C. (1989) Link between D, and D2 dopamine receptors is reduced in schizophrenia and Hunting-ton’s diseased brain. Proc. Natl. Acad. Sci. USA 86, 10,156–10, 160.Google Scholar
  113. 113.
    Mamelak, M., Chiu, S., and Mishra, R. K. (1993) High and low affinity states of dopamine D, receptors in schizophrenia. Eur. J. Pharmacol. 233, 175, 176.Google Scholar
  114. 114.
    Schmauss, C., Hartounian, V., Davis, K. L., and Davidson, M. (1993) Selective loss of dopamine D3-type receptor mRNA expression in parietal and motor cortices of patients with chronic schizophrenia. Proc. Natl. Acad. Sci. USA 90, 8942–8946.PubMedCrossRefGoogle Scholar
  115. 115.
    Knable, M. B., Hyde, T. M., Herman, M. M., Carter, J. M., Bigelow, L., and Kleinman, J. E. (1994) Quantitative autoradiography of dopamine D, receptors, D2 receptors, and dopamine uptake sites in postmortem striatal specimens from schizophrenic patients. Biol. Psychiatry 36, 827–835.PubMedCrossRefGoogle Scholar
  116. 116.
    Kessler, R. M., Whetsell, W. O., Sib Ansari, M. S., Tamminga, C. A., and Mason, N. S. (1995) [125I]Epidepride binding in postmortem brain of schizophrenic subjects. Schizophrenia Res. 15(1–2) 62.Google Scholar
  117. 117.
    Joyce, J. N., Gurevich, E. V., Kung, H. F., Kung, M.-P., Bordelon, Y., Shapiro, P., Arnold, S. E., and Gur, R. E. (1995) Dopamine D3 receptors are elevated in schizophrenic brain and decreased by neuroleptic treatment. Schizophrenia Res. 15 (1 2), 61.CrossRefGoogle Scholar
  118. 118.
    Crow, T. J., Cross, A. J., Johnstone, E. C., Owen, F., Owens, D. G., and Waddington, J. L. (1982) Abnormal involuntary movements in schizophrenia: are they associated with changes in dopamine receptors? J. Clin. Psychopharmacol. 2, 336–340.PubMedCrossRefGoogle Scholar
  119. 119.
    Crow, T. J., Owen, F., Cross, A. J., Ferrier, N., Johnstone, E. C., McCreadie, R. M., Owens, D. G., and Poulter, M. (1981) Neurotransmitter enzymes and receptors in postmortem brain in schizophrenia: evidence that an increase in D2 dopamine receptors in associated with the type I syndrome, in Transmitter Biochemistry of Human Brain Tissue ( Riederer, P. and Usdin, E., eds.), MacMillan, London, pp. 85–96.Google Scholar
  120. 120.
    Seeman, P. and Niznik, H. B. (1990) Dopamine receptors and transporters in Parkinson’s disease and schizophrenia. FASEB J. 4, 2737–2744.PubMedGoogle Scholar
  121. 121.
    Seeman, P., Ulpian, C., Bergeron, C., Riederer, P., Jellinger, K., Gabriel, E., Reynolds, G. P., and Tourtelotte, W. W. (1984) Bimodal distribution of dopamine receptor densities in brains of schizophrenics. Science 225, 728–731.PubMedCrossRefGoogle Scholar
  122. 122.
    Baldessarini, R. J., and Tarsy, D. (1979) Relationship of the actions of neuroleptic drugs to the pathophysiology of tardive dyskinesia. Intl. Rev. Neurobiol. 21, 1–45.CrossRefGoogle Scholar
  123. 123.
    Andreasen, N. C., Carson, R., Diksic, M., Evans, A., Farde, L. O., Gjedde, A., Hakin, A., Lal, S., Nair, N., Sedvall, G., Tune, L., and Wong, D. F. (1988) Workshop on schizophrenia, PET and dopamine D2 receptors in the human neostriatum. Schizophrenia Bull. 14, 471–484.CrossRefGoogle Scholar
  124. 124.
    Baldessarini, R. J., Kula, N. S., Campbell, A., Bakthavachalam, V., Yuan, J., and Neumeyer, J. L. (1992) Prolonged D2 antidopaminergic activity of alkylating and nonalkylating derivatives of spiperone in rat brain. Mol. Pharmacol. 42, 856–863.PubMedGoogle Scholar
  125. 125.
    Memo, M., Kleinman, J. E., and Hanbauer, I. (1983) Coupling of dopamine DI recognition sites with adenylate cyclase in nuclei accumbens and caudatus of schizophrenics. Science 221, 1304–1307.PubMedCrossRefGoogle Scholar
  126. 126.
    Lévesque, D., Martres, M.-P., Diaz, J., Griffon, N., Lammers, C. H., Sokoloff, P., and Schwartz, J.-C. (1995) A paradoxical regulation of the dopamine D3 receptor expression suggests the involvement of an anterograde factor from dopamine neurons. Proc. Natl. Acad. Sci. USA 92, 1719–1723.PubMedCrossRefGoogle Scholar
  127. 127.
    Gelbard, H., Teicher, M. H., Gallitano, A., Marsh, E. R., Zorc, J., Faedda, G., and Baldessarini, R. J. (1990) Dopamine DI receptor development depends on endogenous dopamine. Dey. Brain Res. 56, 137–140.CrossRefGoogle Scholar
  128. 128.
    Hitri, A., Casanova, M. F., Kleinman, J. E., Weinberger, D. R., and Wyatt, R. J. (1995) Age-related changes in [3H]GBR-12935 binding site density in the prefrontal cortex of controls and schizophrenics. Biol. Psychiatry 37, 175–182.PubMedCrossRefGoogle Scholar
  129. 129.
    Madras, B. K., Spealman, R. D., Fahey, M. A., Neumeyer, J. L., Saha, J. K., and Milius, R. A. (1989) Cocaine receptors labeled by [3H]213-carbomethoxy-313-(4-fluorophenyl)tropane. Mol. Pharmacol. 36 518–524.Google Scholar
  130. 130.
    Neumeyer, J. L., Wang, S., Milius, R. A., Baldwin, R. M., Zea-Ponce, Y., Hoffer, P. B., Sybirska, E., Al-Tairiti, M., Chamey, D. S., Malison, R. T., Lamelle, M., and Innis, R. B. (1991) [l231]2ß-Carbomethoxy-313-(4-iodophenyl)-tropane: high affinity SPECT radiotracer for monoamine reuptake sites in brain. J. Med. Chem. 34, 3144–3146.Google Scholar
  131. 131.
    Janowsky, A., Vocci, F., Berger, P., Angel, I., Zelnck, N., Kleinman, J. E., Skolnick, P., and Paul, S. M. (1987) [3H]GBR-12935 binding to the dopamine transporter is decreased in the caudate nucleus in Parkinson’s disease. J. Neurochem. 49, 617–621.Google Scholar
  132. 132.
    Czudek, C. and Reynolds, G. P. (1989) [3H]GBR-12935 binding to the dopamine uptake sites in postmortem brain tissue in schizophrenia. J. Neural Transm. 77, 227–230.Google Scholar
  133. 133.
    Bogerts, B. (1991) The neuropathology of schizophrenia: pathophysiologic and neurodevelopmental implications, in Fetal Neural Development and Adult Schizophrenia ( Mednick, S. A., Cannon, T. D., and Barr, C. E., eds.), Cambridge University Press, London, pp. 153–173.Google Scholar
  134. 134.
    Shapiro, R. M. (1993) Regional neuropathology in schizophrenia: where are we; where are we going? Schizophrenia Res. 10, 187–239.CrossRefGoogle Scholar
  135. 135.
    Trojanowski, J. Q. and Arnold, S. E. (1995) In pursuit of the molecular neuropathology of schizophrenia. Arch. Gen. Psychiatry 52, 274–276.PubMedCrossRefGoogle Scholar
  136. 136.
    Ariano, M. A. and Sibley, D. R. (1994) dopamine receptor distribution in the rat CNS: elucidation using antipeptide antisera directed against DtA and D3 subtypes. Brain Res. 649, 95–110.Google Scholar
  137. 137.
    Boundy, V. A., Luedtke, R. R., Gallitano, A. L., Smith, J. E., Filtz, T. M., Kallen, R. G., and Molinoff, P. B. (1993) Expression and characterization of the rat D3 dopamine receptor: pharmacologic properties and development of antibodies. J. Pharmacol. Exp. Ther. 264, 1002–1011.PubMedGoogle Scholar
  138. 138.
    Baron, J. C., Comar, D., Farde, L. O., Martinot, J. L., and Mazoyer, B. (eds.) (1991) Brain Dopaminergic Systems: Imaging with Positron Tomography. Kluwer, Dordrecht, Germany.Google Scholar
  139. 139.
    Farde, L. O., Nordström, A.-L., Eriksson, L., Halldin, C., and Sedvall, G. (1990) Comparison of methods used with [“C]raclopride and [”C]N-methylspiperone for the PET-determination of central D, dopamine receptors. Clin. Neuropharmacol. 13(Suppl. 2 ), 87, 88.Google Scholar
  140. 140.
    Konig, P., Benzer, M. K., and Fritsche, H. (1991) SPECT technique for visualization of cerebral dopamine D, receptors. Am. J. Psychiatry 148, 1607, 1608.Google Scholar
  141. 141.
    Reba, R. C. (1993) PET and SPECT: opportunities and challenges for psychiatry. J. Clin. Psychiatry 54 (Suppl. 11), 26–32.PubMedGoogle Scholar
  142. 142.
    Ring, H. A. (1995) the value of positron emission tomography in psychopharmacology (1995) Hum. Psychopharmacology 10, 79–87.CrossRefGoogle Scholar
  143. 143.
    Sedvall, G. (1992) The current status of PET scanning with respect to schizophrenia. Neuropsychopharmacology 7, 41–54.PubMedGoogle Scholar
  144. 144.
    Verhoeff, N. P. (1991) Pharmacological implications for neuroreceptor imaging. Eur. J. Nucl. Med. 18, 482–502.PubMedCrossRefGoogle Scholar
  145. 145.
    Weinberger, D. R. (1993) SPECT imaging in psychiatry: introduction and overview. J. Clin. Psychiatry 54 (Suppl. 11), 3–5.PubMedGoogle Scholar
  146. 146.
    Wong, D. F. (1992) PET studies of neuroreceptors in schizophrenia: commentary on the current status of PET scanning with respect to schizophrenia. Neuropsychopharmacology 7, 69–72.PubMedGoogle Scholar
  147. 147.
    Billings, J. J., Kung, M.-P., Chumpradit, S., Mozley, D., Alavi, A., and Kung, H. F. (1992) Characterization of radioiodinated TISCH: a high-affinity and selective ligand for mapping CNS D dopamine receptor. J. Neurochem. 58 277–286.Google Scholar
  148. 148.
    Kung, H. F. (1993) SPECT and PET ligands for CNS imaging. RBI Neurotransmissions 9 (4), 1–6.Google Scholar
  149. 149.
    Kung, M.-P., Kung, H. F., Billings, J., Yang, Y., Murphy, R. A., and Alavi, A. (1990) Characterization of IBF as a new selective dopamine Dz receptor imaging agent. J. Nucl. Med. 31, 648–654.PubMedGoogle Scholar
  150. 150.
    Mazière, B., Coenen, H. H., Halldin, C., Nâgren, K., and Pike, V. W. (1992) PET radioligands for dopamine receptors and reuptake sites: chemistry and biochemistry. Nucl. Med. Biol. 19, 497–512.Google Scholar
  151. 151.
    Stöcklin, G. (1992) Tracers for metabolic imaging of brain and heart. Eur. J. Nucl. Med. 19, 527–551.PubMedCrossRefGoogle Scholar
  152. 152.
    Wong, D. F., Wilson, A. A., Chen, C., Minkin, E., Dannals, R. F., Ravert, H. T., Sanchez-Roa, P., Villemagne, V., and Wagner, J. N., Jr. (1992) In vivo studies of [’25I]iodobenzamide and [“C]iodobenzamide: a ligand suitable for positron emission tomography and single photon emission tomography imaging of cerebral D2 dopamine receptors. Synapse 12, 236–241.PubMedCrossRefGoogle Scholar
  153. 153.
    Farde, L. O., Nyberg, S., Oxenstierna, G., Nakashima, Y., Halldin, C., and Ericsson, B. (1995) Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients. J. Clin. Psychopharmacol. 15 (Suppl. 1), 19–23.CrossRefGoogle Scholar
  154. 154.
    Crawley, C. W., Crow, T. J., Johnstone, E. C., Oldland, S. R., Owen, F., Owens, D. G., Smith, T., Veall, N., and Zanelli, G. D. (1986) Uptake of 76Br-spiperone in the striata of schizophrenic patients and controls. Nucl. Med. Commun. 7, 599–607.PubMedCrossRefGoogle Scholar
  155. 155.
    Wong, D. F., Wagner, H. N., Jr., Tune, L. E., Dannals, R. F., Pearlson, G. D., Links, J. M., Tamminga, C. A., Broussolle, E. P., Ravert, H. T., Wilson, A. A., Toung, J. K., Malat, J., Williams, J. A., O’Tauma, L. A., Snyder, S. H., Kuhar, M. J., and Gjedde, A. (1986) Positron emission tomography reveals elevated D2 dopamine receptors in drug-naïve schizophrenics. Science 234, 1558–1563.PubMedCrossRefGoogle Scholar
  156. 156.
    Wong, D. F., Singer, H., Pearlson, G., Tune, L., Ross, C., Villemagne, V., Dannals, R. F., Links, J. M., Wilson, A., Ravert, H., Wagner, H. N., Jr., and Gjedde, A. (1988) D2 dopamine receptors in Tourette’s syndrome and manic-depressive illness. J. Nucl. Med. 29, 820, 821.Google Scholar
  157. 157.
    Blin, J., Baron, J. C., Cambon, H., Bonnet, A. M., DuBois, D., Loc’h, C., Mazière, B., and Agid, Y. (1989) Striatal dopamine D2 receptors in tardive dyskinesia: PET study. J. Neurol. Neurosurg. Psychiatry 52, 1248–1252.PubMedCrossRefGoogle Scholar
  158. 158.
    Martinot, J.-L., Peron-Magna, P., Huret, J.-D., Mazoyer, B., Baron, J.-C., Boulenger, J.-P., Loc’h, C., Mazière, B., Caillard, V., Loo, H., and Syrota, A. (1990) Striatal D2 dopaminergic receptors assessed with positron emission tomography and [76Br]bromospiperone in untreated schizophrenic patients. Am. J. Psychiatry 147, 44–50.PubMedGoogle Scholar
  159. 159.
    Martinot, J.-L., Paillère-Martinot, M. L., Loc’h, C., Hardy, P., Poirier, M. F., Mazoyer, B., Beaufils, B., Mazière, B., Allilaire, J. F., and Syrota, A. (1991) The estimated density of D2 striatal receptors in schizophrenia: a study with positron emission tomography and [76Br]bromolisuride. Br. J. Psychiatry 158, 346–350.PubMedCrossRefGoogle Scholar
  160. 160.
    Nordström, A.-L., Farde, L. O., Pauli, S., Litton, J.-E., and Halldin, C. (1992) PET analysis of central [“C]raclopride binding in healthy young adults and schizophrenic patients: reliability and age effects. Hum. Psychopharmacology 7, 157–165.CrossRefGoogle Scholar
  161. 161.
    Suhara, T., Nakayama, K., Inoue, O., Fukuda, H., Shimizu, M., Mori, A., and Tateno, Y. (1992) D dopamine receptor binding in mood disorders measured by positron emission tomography. Psychopharmacology 106, 14–18.PubMedCrossRefGoogle Scholar
  162. 162.
    Pearlson, G. D., Tune, L. E., Wong, D. F., Aylward, E. H., Barta, P. E., Powers, R. E., Tien, A. Y., Chase, G. A., Harris, G. J., and Rabins, P. V. (1993) Quantitative D2 dopamine receptor PET and structural MRI changes in late-onset schizophrenia. Schizophrenia Bull. 19, 783–795.CrossRefGoogle Scholar
  163. 163.
    Tune, L. E., Wong, D. F., Pearlson, G., Strauss, M., Young, T., Shaya, E. K., Dannals, R. F., Wilson, A. A., Ravert, H. T., Sapp, J., Cooper, T., Chase, G. A., and Wagner, H. N., Jr. (1993) Dopamine D2 receptor density estimates in schizophrenia: a positron emission tomography study with “C-N-methylspiperone. Psychiatry Res. 49, 219–237.PubMedCrossRefGoogle Scholar
  164. 164.
    D’haenen, H. A. and Bossuyt, A. (1994) Dopamine D2 receptors in depression measured with single photon emission computed tomography. Biol. Psychiatry 35, 128–132.PubMedCrossRefGoogle Scholar
  165. 165.
    Ebert, D., Feistel, H., Kaschka, W., Barocka, A., and Pirner, A. (1994) Single photon emission computerized tomography assessment of cerebral dopamine D2 receptor blockade in depression before and after sleep deprivation—preliminary results. Biol. Psychiatry 35, 880–885.PubMedCrossRefGoogle Scholar
  166. 166.
    Hietala, J., Syvälahti, E., Vuorio, K., Nägren, K., Lehikoinen, P., Ruotsalainen, U., Räkkäpläinen, V., Lehtinen, V., and Wegelius, U. (1994) Striatal D2 dopamine receptor characteristics in neuroleptic-naïve schizophrenic patients studied with positron emission tomography. Arch. Gen. Psychiatry 51, 116–123.PubMedCrossRefGoogle Scholar
  167. 167.
    Martinot, J.-L., Paillère-Martinot, M. L., Loc’h, C., Lecrubier, Y., Dao-Castellana, M. H., Aubin, F., Allilaire, J. F., Mazoyer, B., Mazière, B., and Syrota, A. (1994) Central D2 receptors and negative symptoms of schizophrenia. Br. J. Psychiatry 164, 27–34.PubMedCrossRefGoogle Scholar
  168. 168.
    Pilowsky, L. S., Costa, D. C., Ell, P. J., Murray, R. M., Verhoeff, N. P., and Kerwin, R. W. (1994) D2 dopamine receptor binding in the basal ganglia of antipsychoticfree schizophrenic patients: an t23I-IBZM single photon emission computerized tomographic study. Br. J. Psychiatry 164, 16–26.PubMedCrossRefGoogle Scholar
  169. 169.
    Knable, M. B., Gonzalez, J., Coppola, R., Jones, D. W., Nawroz, S., Gorey, J., and Weinberger, D. R. (1995) 123I-IBZM SPECT in neuroleptic-free schizophrenic patients. Schizophrenia Res. 15(1–2) 88.Google Scholar
  170. 170.
    Tune, L. E., Wong, D. F., and Pearlson, G. D. (1992) Elevated dopamine D2 receptor density in 23 schizophrenic patients: a positron emission tomography study with [“C]N-methylspiperone. Schizophrenia Res. 6, 147.Google Scholar
  171. 171.
    Farde, L. O., Wiesel, F.-A., Hall, H., Halldin, C., Stone-Elander, S., and Sedvall, G. (1987) No D2 receptor increase in PET study of schizophrenia. Arch. Gen. Psychiatry 44, 671–675.PubMedCrossRefGoogle Scholar
  172. 172.
    Farde, L. O., Wiesel, F.-A., Stone-Elander, S., Halldin, C., Nordstrom, A.-L., Hall, H., and Sedvall, G. (1990) D2 dopamine receptors in neuroleptic-naïve schizophrenic patients. Arch. Gen. Psychiatry 47, 213–219.PubMedCrossRefGoogle Scholar
  173. 173.
    Hall, H., Wedel, I., Halldin, C., Kopp, J., and Farde, L. (1990) Comparison of the in vitro receptor binding properties of [3H]-N-methylspiperone and [3H]raclopride to rat and human brain membranes. J. Neurochem. 55, 2048–2057.PubMedCrossRefGoogle Scholar
  174. 174.
    Logan, J., Dewey, S. L., Wolf, A. P., Fowler, J. S., Brodie, J. D., Angrist, B., Wolkow, N. D., and Gatley, S. J. (1991) Effects of endogenous dopamine on measures of [’SF]N-methylspiroperidol binding in the basal ganglia: comparison of simulations and experimental results from PET studies in baboons. Synapse 9, 195–207.PubMedCrossRefGoogle Scholar
  175. 175.
    Young, L. T., Wong, D. F., Goldman, S., Minkin, E., Chen, C., Matsumura, K., Scheffel, U., and Wagner, H. N., Jr. (1991) Effects of endogenous dopamine on kinetics of [3H]N-methylspiperone and [3H]raclopride binding in the rat brain. Synapse 9, 188–194.PubMedCrossRefGoogle Scholar
  176. 176.
    TenBrink, R. E. and Huff, R. M. (1994) Recent advances in dopamine D3 and D4 receptor ligands and pharmacology. Ann. Rep. Med. Chem. 2, 43–52.CrossRefGoogle Scholar
  177. 177.
    Dewey, S. L., Logan, J., Wolf, A. P., Brodie, J. D., Angrist, B., Fowler, J. S., and Volkow, N. D. (1991) Amphetamine induced decreases in [18F]N-methylspiroperidol binding in the baboon brain using positron emission tomography (PET). Synapse 7, 324–327.PubMedCrossRefGoogle Scholar
  178. 178.
    Dewey, S. L., Smith, G. S., Logan, J., Brodie, J. D., Simkowitz, P., MacGregor, R. R., Fowler, J. S., Volkow, N. D., and Wolf, A. P. (1993) Effects of central cholinergic blockade on striatal dopamine release measured with positron emission tomography in normal human subjects. Proc. Natl. Acad. Sci. USA. 90, 11,816–11, 820.Google Scholar
  179. 179.
    Reith, J., Benkelfat, C., Sherwin, A., Yasuhara, Y., Kuwabara, H., Andermann, F., Bachneff, S., Cumming, P., Diksic, M., Dyve, S. E., Etienne, P., Evans, A. C., Lal, S., Shevell, M., Savard, G., Wong, D. F., Chouinard, G., and Gjedda, A. (1994) Elevated DOPA decarboxylase activity in living brain of patients with psychosis. Proc. Natl. Acad. Sci. USA 91, 11,651–11, 654.Google Scholar
  180. 180.
    Wong, D. F., Pearlson, G. D., Young, L. T., Singer, H., Villemagne, V., Tune, L., Ross, C., Dannals, R. F., Links, J. M., Chan, B., Wilson, A. A., Ravert, H. T., Wagner, H. N., Jr., and Gjedde, A. (1989) D2 dopamine receptors are elevated in neuropsychiatric disorders other than schizophrenia. J. Cereb. Blood FlowMetabol. 9 (Suppl. 1), 593S.Google Scholar
  181. 181.
    Chabriat, H., Levasseur, M., Vidailhet, M., Loc’h, C., Mazière, B., Bourguignon, M. H., Bonnet, A. M., Zilbovicius, M., Raynaud, C., Agid, Y., Syrota, A., and Samson, Y. (1992) In vivo SPECT imaging of D2 receptor with 1231-iodolisuride: results in supranuclear palsy. J. Nucl. Med. 33, 1481–1485.PubMedGoogle Scholar
  182. 182.
    Rutgers, A. W., Lakke, J. P., Paans, A. M., Vaalburg, W., and Korf, J. (1987) Tracing of dopamine receptors in hemiparkinsonism with positron emission tomography (PET). J. Neurol. Sci. 80, 237–248.PubMedCrossRefGoogle Scholar
  183. 183.
    Sawle, G. V., Playford, E. D., Brooks, D. J., Quin, N., and Fackowiack, R. S. (1993). Asymmetrical presynaptic and postsynaptic changes in the striatal dopamine projection in DOPA-naïve parkinsonism. Brain 116, 853–867.PubMedCrossRefGoogle Scholar
  184. 184.
    Carroll, F. I., Lewin, A. H., Boja, J. W., and Kuhar, M. J. (1992) Cocaine receptor: biochemical characterization and structure—activity relationships of cocaine analogs at the dopamine transporter. J. Med. Chem. 35, 969–981.PubMedCrossRefGoogle Scholar
  185. 185.
    Frost, J. J., Rosier, A. J., Reich, S. G., Smith, J. S., Ehlers, M. D., Snyder, S. H., Ravert, H. T., and Dannals, R. F. (1993) Positron emission tomographic imaging of the dopamine transporter with [“C] WIN-35428 reveals marked declines in mild Parkinson’s disease. Ann. Neurology 34, 423–431.CrossRefGoogle Scholar
  186. 186.
    Innis, R. B., Seibyl, J. P., Scanley, B. E., Laruelle, M., Abi-Dargham, A., Wallace, E., Baldwin, R. M., Zea-Ponce, Y., Zoghbi, S., Wang, S., Gao, Y., Neumeyer, J. L., Charney, D. S., Hoffer, P. B., and Marek, K. L. (1993) Single photon emission computed tomographic imaging demonstrates loss of striatal monoamine transporters in Parkinson’s disease. Proc. Natl. Acad. Sci. USA 90, 11,965–11, 969.Google Scholar
  187. 187.
    Farde, L. O., Nordström, A.-L., Wiesel, F.-A., Pauli, S., Halldin, C., and Sedvall, G. (1992) Positron emission tomographic analysis of central D, and D2 receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch. Gen. Psychiatry 49, 538–544.PubMedCrossRefGoogle Scholar
  188. 188.
    Farde, L. O., Wiesel, F.-A., Halldin, C., and Sedvall, G. (1988) Central D,-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch. Gen. Psychiatry 45, 71–76.Google Scholar
  189. 189.
    Smith, M., Wolf, A. P., Brodie, J. D., Arnett, C. D., Barouche, F., Shiue, C.-Y., Fowler, J. S., Russell, J. A., MacGregor, R. R., Wolkin, A., Angrist, B., Rotrosen, J., and Peselow, E. (1988) Serial [18F]N-methylspiroperidol PET studies to measure changes in antipsychotic drug D2 receptor occupancy in schizophrenic patients. Biol. Psychiatry 23, 653–663.PubMedCrossRefGoogle Scholar
  190. 190.
    Cambon, H., Baron, J. C., Boulenger, J. P., Loc’h, C., Zarifian, E., and Mazière, B. (1987) In vivo assay for neuroleptic receptor binding in the striatum. Br. J. Psychiatry 151, 824–830.PubMedCrossRefGoogle Scholar
  191. 191.
    Wolkin, A., Brodie, J. D., Barouche, F., Rotrosen, J., Wolf, A. P., Smith, M., Fowler, J. S., and Cooper, T. B. (1989) Dopamine receptor occupancy and plasma haloperidol levels. Arch. Gen. Psychiatry 46, 482–484.PubMedCrossRefGoogle Scholar
  192. 192.
    Brücke, T., Roth, J., Podreka, I., Strobl, R., Wegner, S., and Asenbaum, S. (1992) Striatal dopamine D2-receptor blockade by typical and atypical neuroleptics. Lancet 339, 497.PubMedCrossRefGoogle Scholar
  193. 193.
    Nordström, A.-L., Farde, L. O., Wiesel, F.-A., Forslund, K., Pauli, S., Halldin, C., and Uppfeldt, G. (1993) Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenia patients. Biol. Psychiatry 33, 227–235.PubMedCrossRefGoogle Scholar
  194. 194.
    Nordström, A.-L., Farde, L. O., and Halldin, C. (1992) Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol. Psychopharmacology 106, 433–438.PubMedCrossRefGoogle Scholar
  195. 195.
    Nordström, A.-L., Farde, L. O., and Halldin, C. (1993) High 5-HT2 receptor occupancy in clozapine treated patients demonstrated by PET. Psychopharmacology 110, 365–367.PubMedCrossRefGoogle Scholar
  196. 196.
    Baldessarini, R. J., Cohen, B. M., and Teicher, M. H. (1988) Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch. Gen. Psychiatry 45, 79–91.PubMedCrossRefGoogle Scholar
  197. 197.
    Baron, J. C., Martinot, J. L., Cambon, H., Boulenger, J. P., Poirir, M. F., Caillard, V., Blin, J., Huret, J. D., Loc’h, C., and Mazière, B. (1989) Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels. Psychopharmacology 99, 463–472.PubMedCrossRefGoogle Scholar
  198. 198.
    Nyberg, S., Farde, L. O., Halldin, C., Dahl, M.-L., and Bertilson, L. (1995) D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am. J. Psychiatry 152, 173–178.PubMedGoogle Scholar
  199. 199.
    Pickar, D., Su, T.-P., Coppola, R., Lee, C. S., Hsiao, J. K., Breier, A., and Weinberger, D. R. (1995) D2 occupancy and dopamine release determined by’ 23I-IBZM SPECT following clozapine dose reduction. Schizophrenia Res. 15 (1–2), 96.CrossRefGoogle Scholar
  200. 200.
    Pilowsky, L. S., Costa, D. C., Ell, P. J., Murray, R. M., Verhoeff, N. P., and Kerwin, R. W. (1992) Clozapine, single photon emission tomography, and the D 2 dopamine receptor blockade hypothesis of schizophrenia. Lancet 340, 199–202.PubMedCrossRefGoogle Scholar
  201. 201.
    Cohen, B. M., Tsuneizumi, T., Baldessarini, R. J., Campbell, A., and Babb, S. (1992) Differences between antipsychotic drugs in persistence of brain levels and behavioral effects. Psychopharmacology 108, 338–344.PubMedCrossRefGoogle Scholar
  202. 202.
    Hubbard, J. W., Ganes, D., and Midha, K. K. (1987) Prolonged pharmacologic activity of neuroleptic drugs. Arch. Gen. Psychiatry 44, 99, 100.Google Scholar
  203. 203.
    Schotte, A., Janssen, P. F., Gommeren, W., Luyten, W. H., and Leysen, J. E. (1992) Autoradiographic evidence for the occlusion of rat brain dopamine D3 receptors in vivo. Eur. J. Pharmacol. 218, 373–375.PubMedCrossRefGoogle Scholar
  204. 204.
    Meltzer, H. Y. (ed.) (1992) Novel Antipsychotic Drugs. Raven, New York.Google Scholar
  205. 205.
    Sokoloff, P., Martres, M. P., Giros, B., Bouthenet, M. L., and Schwartz, J.-C. (1992) The third dopamine receptor (D3) as a novel target for antipsychotics. Biochem. Pharmacol. 43, 659–666.PubMedCrossRefGoogle Scholar
  206. 206.
    Baldessarini, R. J., Kula, N. S., McGrath, C., Kebabian, J. W., and Neumeyer, J. L. (1993) Isomeric selectivity of D3 dopamine receptors. Eur. J. Pharmacol. 239, 269, 270.Google Scholar
  207. 207.
    Chumpradit, S., Kung, M.-P., and Kung, H. F. (1993) Synthesis and optical resolution of (R) and (S)-trans-7-hydroxy-2-[N-propyl-N-(3’-iodo’-2’-propenyl) amino]tetralin: a new D3 dopamine receptor ligand. J. Med. Chem. 36, 4308–4312.PubMedCrossRefGoogle Scholar
  208. 208.
    DeWald, H. A., Heffner, T. G., Jaen, J. C., Lustgarten, D. M., McPhail, A. T., Meltzer, L. T., Pugsley, T. A., and Wise, L. D. (1990) Synthesis and dopamine agonist properties of (±)-trans-3,4,4a,1Ob-tetrahyro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol and its enantiomers. J. Med. Chem. 33, 445–450.PubMedCrossRefGoogle Scholar
  209. 209.
    Sokoloff, P., Giros, B., Martres, M. P., Bouthenet, M. L., and Schwartz, J.-C. (1990) Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347, 146–151.PubMedCrossRefGoogle Scholar
  210. 210.
    Waters, N., Lagerkvist, S., Löfberg, L., Piercey, M., and Carlsson, A. (1993) The dopamine D3 receptor and autoreceptor preferring antagonists (+)-AJ76 and (+)UH232: a microdialysis study. Eur. J. Pharmacol. 242, 151–163.PubMedCrossRefGoogle Scholar
  211. 211.
    Burris, K. D., Filtz, T. M., Chumpradit, S., Kung, M.-P., Foulon, C., Hensler, J. G., Kung, H., and Molinoff, P. B. (1994) Characterization of [’ 25I]-trans-7-hydroxy-2[(N-propyl-N-3’-iodo-2’-propenyl)amino]tetralin binding to dopamine D3 receptors in rat olfactory tubercle. J. Pharmacol. Exp. Ther. 268, 935–942.Google Scholar
  212. 212.
    Booth, R. G., Baldessarini, R. J., and Marsh, E. R. (1994) Effects of a D3-selective aminotetralin on dopamine metabolism in rat brain regions in vitro and in vivo. Brain Res. 662, 283–288.PubMedCrossRefGoogle Scholar
  213. 213.
    Malmberg, A., Jackson, D. M., Eriksson, A., and Mohell, N. (1993) Unique binding characteristics of antipsychotic agents interacting with human dopamine D2A, D2B, and D3 receptors. Mol. Pharmacol. 43, 749–754.PubMedGoogle Scholar
  214. 214.
    Lahti, R. A., Evans, D. L., Stratman, N. C., and Figur, L. M. (1993) Dopamine D, vs. D2 receptor selectivity of dopamine receptor antagonists: possible therapeutic implications. Eur. J. Pharmacol. 236, 483–486.PubMedCrossRefGoogle Scholar
  215. 215.
    Seeman, P. and Van Tol, H. H. (1993) Dopamine D, receptors bind inactive (+)aporphines, suggesting a neuroleptic role: sulpiride not stereoselective. Eur. J. Pharmacol. 233, 173, 174.Google Scholar
  216. 216.
    Campbell, A., Yeghiayan, S., Baldessarini, R. J., and Neumeyer, J. L. (1991) Selective antidopaminergic effects of S(+) N-n-propylnoraporphines in limbic vs. extrapyramidal sites in rat brain: comparisons with typical and atypical anti-psychotic agents. Psychopharmacology 103, 323–329.PubMedCrossRefGoogle Scholar
  217. 217.
    Kula, N. S., Baldessarini, R. J., Kebabian, J. W., and Neumeyer, J. L. (1994) S(+)aporphines are not selective for human D3 dopamine receptors. Cell. Mol. Neurobiology 14, 185–191.CrossRefGoogle Scholar
  218. 218.
    Baldessarini, R. J., Campbell, A., Ellingboe, J., Zong, R., and Neumeyer, J. L. (1994) Effects of aporphine isomers on rat prolactin. Neurosci. Lett. 176, 269–271.PubMedCrossRefGoogle Scholar
  219. 219.
    Campbell, A., Baldessarini, R. J., and Neumeyer, J. L. (1993) Altered spontaneous behavior and sensitivity to apomorphine in rats following pretreatment with S(+)-aporphines or fluphenazine. Psychopharmacology 111, 351–358.PubMedCrossRefGoogle Scholar
  220. 220.
    Baldessarini, R. J. and Tarazi, F. I. (1996) Brain dopamine receptors: a primer on their current status, basic and clinical. Harvard Rev. Psychiatry 3, 301–325.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1997

Authors and Affiliations

  • Ross J. Baldessarini

There are no affiliations available

Personalised recommendations